Bayer Aktienges Ads (BAYRY) 136.5000 $BAYRY
Business events scheduled for the coming month
By The Associated Press - AP - Fri Mar 28, 1:03PM CDT
TUESDAY, April 1
Simulations Plus Predictor improves all predictions, adds new ones
M2 - Thu Mar 27, 7:43AM CDT
Simulations Plus, Inc. (NASDAQ: SLP) said it has released version 7.0 of its best-in-class ADMET Predictor molecular property prediction software.
Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 27, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rh34nq/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs, namely, aminoglycosides, B-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides and phenicols. The market for these classes has been extensively analyzed on the basis of the leading drug launch, expiry, efficacy, sales revenue and geographic presence. The market size and forecast in terms of USD million for each of these classes has been provided for the period 2011 to 2019, considering 2012 as the base year. The report on antibacterial drugs market also provides % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 to 2019. Key Topics Covered: Preface Executive Summary Market Overview Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/rh...ibacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Simulations Plus Releases ADMET Predictor Version 7.0
Business Wire - Wed Mar 26, 7:02AM CDT
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has released version 7.0 of its best-in-class ADMET Predictor(TM) molecular property prediction software.
Bayer Names Carnegie Science Center Recipient of $150,000 Bayer USA Foundation Grant
PR Newswire - Wed Mar 26, 7:00AM CDT
Bayer Corporation announced today that the Bayer USA Foundation has awarded the Carnegie Science Center (CSC) a three-year grant totaling $150,000 to support a range of STEM-related (science, technology, engineering and mathematics) programs, events and competitions at CSC's new Center for STEM Education and Career Development.
Global Dermatological Drugs Market 2014-2018: The Global Dermatological Drugs Market is Expected to Reap Large Revenues with Increasing Use of Biologics
M2 - Wed Mar 26, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/22gwrb/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Dermatological Drugs market to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market's growth is an increase in the aging population worldwide. The Global Dermatological Drugs market has also been witnessing a spurt in the use of biologics. However, the risk of adverse side effects associated with dermatological drugs could pose a challenge to the growth of this market. Key vendors dominating this space include AbbVie Inc., Galderma S.A., Johnson & Johnson Ltd., Novartis AG, Stiefel Laboratories Inc., and Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA. Commenting on the report, an analyst from the team said: Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. For more information visit http://www.researchandmarkets.com/research/22gwrb/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Global Hygiene Adhesives Market 2014-2018 with Bostik SA, H.B. Fuller Co., and Henkel AG & Co. KGaA. Dominating
M2 - Tue Mar 25, 11:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qh3qb5/global_hygiene) has announced the addition of the "Global Hygiene Adhesives Market 2014-2018" report to their offering. One of the main drivers in the Global Hygiene Adhesives market is the increasing focus vendors place on R&D. Vendors in this market are increasing their focus toward developing products that meet the standards set by the regulatory bodies monitoring the environment. In addition, changing customers' requirements, changing competitive scenarios, changing market dynamics, and better performance and productivity of technologically developed products, are the other key factors that are leading to vendors increasing their spending in R&D. Commenting on the report, an analyst from the team said: Emerging markets, such as China and India, are witnessing an increase in demand for hygiene products such as baby diapers and feminine napkins. This is due to the increasing preference shown by consumers in these regions as a result of the increase in their disposable income. However, it has been estimated that the penetration of baby diapers is approximately 20 percent in China and is less than 10 percent in India. This, therefore, creates a huge potential for vendors providing baby diapers to tap the unserved market and increase their market share. Vendors in the Global Hygiene Product market are also focusing on developing new hygiene products to meet the growing demand and to increase the use of hygiene products in these regions. Therefore, as the demand for hygiene products grows in these regions, the demand for hygiene adhesives is also expected to grow. Furthermore, vendors in the Global Hygiene Product market, who are the key end-users in the Global Hygiene Adhesives market, will also require new and innovative hygiene adhesive solutions from vendors in the Global Hygiene Adhesives market. This will result in them developing new and innovative hygiene products, thereby driving the growth in the market during the forecast period Further, the report states that despite the presence of several drivers, the growth of the Global Hygiene Adhesives market is curtailed by several challenges. One such challenge hindering the growth of the market is the increasing cost of raw materials. The increase in the requirement of raw materials by vendors to meet the rising demand for hygiene adhesives has increased the raw material supplier's power to price them as they deem fit. In addition, the increasing demand for raw materials in other application areas such as construction, packaging, and furniture making is also contributing to the volatility in raw material prices. Key vendors dominating this space are: - Bostik SA - H.B. Fuller Co. - Henkel AG & Co. KGaA. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Overview of Global Adhesives Market 07. Market Landscape 08. Market Segmentation by Application 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis Other Companies Featured: - 3M Corp. - Abifor AG - ADTEK Malaysia Sdn Bhd - ALFA Klebstoffe AG - Avery Dennison Corp. - BASF SE - Bayer AG - Beardow and Adams (Adhesives) Ltd. - C. L. Hauthaway Corp. - Clifton Adhesive Inc. - Cytec Industries Inc. - Eastman Chemical Company - Evonik Industries AG - Exxon Mobil Corp. - H.B. Fuller Co. - Huntsman Corp. - Ichemco srl. - Jowat AG - Lohmann GmbH & Co.KG - MACtac - OMNOVA Solutions Inc. - Sika AG - The Dow Chemical Co. - The Reynolds Co. - VIXXOL Corp. For more information visit http://www.researchandmarkets.com/research/qh...al_hygiene
Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating
M2 - Tue Mar 25, 10:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3c75md/global) has announced the addition of the "Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating" report to their offering. The Global Atherectomy and Thrombectomy Devices market to grow at a CAGR of 9.36 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing prevalence of abdominal aortic aneurysm and peripheral artery disease. The Global Atherectomy and Thrombectomy Devices market has also been witnessing the increase in demand for minimally invasive procedures. However, the lack of awareness about peripheral vascular disease among patients could pose a challenge to the growth of this market. There is an increasing demand for minimally invasive surgery among the rapidly increasing aging population in the world, and this is expected to propel the growth of the Global Atherectomy and Thrombectomy Devices market. Minimally invasive endovascular procedures are performed through minute incisions in the body. Such procedures can be used to treat plaque blockages in the arteries of the heart and other vessel walls of peripheral organs such as kidneys and brain. The principal advantages of these procedures, over conventional surgical methods, are the short recovery time, less physical trauma, minimal scarring, low risk of infection, minimal bleeding, low cost, and shorter hospital stays. Therefore, the increasing demand for minimally invasive surgery is expected to increase the demand for atherectomy and thrombectomy devices during the forecast period. Further, the report states that one of the major challenges faced by vendors in the market is the lack of awareness about PVDs among patients. This is primarily due to the asymptomatic nature of vascular diseases, wherein patients do not realize and are unaware of the immediate symptoms. The key vendors dominating this market space are: - Bayer AG - Boston Scientific Corp. - Covidien plc - Cardiovascular Systems Inc. - Spectranetics Corp. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Global Atherectomy and Thrombectomy Market 07. Market Segmentation by Product Category 08. Geographical Segmentation 09. Global Atherectomy Market 10. Market Segmentation by Product Type 11. Geographical Segmentation 12. Global Thrombectomy Devices Market 13. Market Segmentation by Procedure 14. Geographical Segmentation 15. Buying Criteria 16. Market Growth Drivers 17. Drivers and their Impact 18. Market Challenges 19. Impact of Drivers and Challenges 20. Market Trends 21. Trends and their Impact 22. Vendor Landscape For more information visit http://www.researchandmarkets.com/research/3c75md/global
1 Piece of News That Could Move Exelixis
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 24, 6:53PM CDT
Investors will soon learn whether Exelixis will be able to expand the use of its Cometriq cancer drug beyond its current indication as a therapy for medullary thyroid cancer, or MTC. Exelixis completed enrollment of patients in a phase 3 study...
3 Upcoming FDA Meetings You Should be Watching
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:05PM CDT
Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to...
Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
M2 - Fri Mar 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tp6b8p/diffuse_large) has announced the addition of the Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 report to their offering. Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Diffuse Large B-Cell Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diffuse Large B-Cell Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: Table of Contents Table of Contents List of Tables List of Figures Introduction Diffuse Large B-Cell Lymphoma Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Unaccomplished Trials of Diffuse Large B-Cell Lymphoma Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Prominent Drugs Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma Dec 09, 2013: Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial Aug 15, 2013: Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma Jun 16, 2013: Pharmacyclics Announces Results Of Two Phase II Ibrutinib Studies In Patients With Mantle Cell Lymphoma Or Diffuse Large B-Cell Lymphoma Jun 10, 2013: Immunomedics's 90Y-Epratuzumab Study Shows Improvement Of Therapy Results Following R-CHOP In Patients With Diffuse Large B-Cell Lymphoma May 10, 2013: Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint In Diffuse Large B-Cell Lymphoma Clinical Trial Profiles Clinical Trial Overview of Top Companies F. Hoffmann-La Roche Ltd. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Celgene Corporation Clinical Trial Overview of Celgene Corporation Amgen Inc. Clinical Trial Overview of Amgen Inc. Novartis AG Clinical Trial Overview of Novartis AG Takeda Pharmaceutical Company Limited Clinical Trial Overview of Takeda Pharmaceutical Company Limited Pharmacyclics, Inc. Clinical Trial Overview of Pharmacyclics, Inc. GlaxoSmithKline plc Clinical Trial Overview of GlaxoSmithKline plc Bayer AG Clinical Trial Overview of Bayer AG AstraZeneca PLC Clinical Trial Overview of AstraZeneca PLC Immunomedics, Inc. Clinical Trial Overview of Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government National Cancer Institute Clinical Trial Overview of National Cancer Institute Fred Hutchinson Cancer Research Center Clinical Trial Overview of Fred Hutchinson Cancer Research Center Groupe d'Etudes de Lymphomes de L'Adulte Clinical Trial Overview of Groupe d'Etudes de Lymphomes de L'Adulte Mayo Clinic Clinical Trial Overview of Mayo Clinic The University of Texas M. D. Anderson Cancer Center Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center FUDAN University Clinical Trial Overview of FUDAN University Memorial Sloan Kettering Cancer Center Clinical Trial Overview of Memorial Sloan Kettering Cancer Center The Lymphoma Academic Research Organisation Clinical Trial Overview of The Lymphoma Academic Research Organisation Massachusetts General Hospital Clinical Trial Overview of Massachusetts General Hospital Stanford University Clinical Trial Overview of Stanford University Five Key Clinical Profiles Appendix Abbreviations Definitions Research Methodology Secondary Research About Us Contact Us Disclaimer Source List of Tables Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Suspended Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Withdrawn Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Terminated Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Immunomedics, Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Groupe d'Etudes de Lymphomes de L'Adulte, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The Lymphoma Academic Research Organisation, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014- List of Figures Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2014- Therapeutics, Global, Clinical Trials In Progress by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- GlobalData Methodology For more information visit http://www.researchandmarkets.com/research/tp...fuse_large About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Can These Companies Bounce Back from Disappointing Sales?
Dan Carroll, The Motley Fool - Motley Fool - Fri Mar 21, 8:30AM CDT
Bristol-Myers Squibb and Pfizer have rallied back from the patent cliff as well as any companies in big pharma, and both these standout firms have looked toward the future in igniting investor optimism. But one drug captured all the hype around...
Why Pfizer Investors Should Watch Quark This Summer
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 19, 1:30PM CDT
Pfizer may learn whether it has a potential challenger to Novartis' and Roche's Lucentis and Regeneron and Bayer's Eylea soon. Its development partner, Quark Pharmaceuticals , is expected to complete its phase 2b study of PF-655 in...
Update on Bayer's Adempas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 17, 1:23PM CDT
Bayer initiated the phase IIIb study on Adempas.
5 Big Pharma Stocks With the Strongest Ties to Emerging Markets
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 16, 1:05PM CDT
The life of a buy-and-hold pharmaceuticals investor used to be fairly simple in the 1990s and 2000s. They would sit back, relax, and enjoy their 80%-plus gross margin and premium dividend yield without a care in the world. But times have changed. ...
Siemens' Microbiology Unit Up for Sale? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 4:00PM CDT
According to a Bloomberg report, Siemens is contemplating the sale of its microbiology unit to stop the slide in profitability.
Bright Outlook at Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 3:45PM CDT
Bayer divulged its sales growth expectations for three of its major segments through 2016.
Bayer/Amgen's Nexavar Fails in Late-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:45PM CDT
Bayer and Amgen announced disappointing results from a phase III study on Nexavar.
Business events scheduled for the coming month
By The Associated Press - AP - Fri Mar 28, 1:03PM CDT
TUESDAY, April 1
Simulations Plus Predictor improves all predictions, adds new ones
M2 - Thu Mar 27, 7:43AM CDT
Simulations Plus, Inc. (NASDAQ: SLP) said it has released version 7.0 of its best-in-class ADMET Predictor molecular property prediction software.
Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 27, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rh34nq/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs, namely, aminoglycosides, B-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides and phenicols. The market for these classes has been extensively analyzed on the basis of the leading drug launch, expiry, efficacy, sales revenue and geographic presence. The market size and forecast in terms of USD million for each of these classes has been provided for the period 2011 to 2019, considering 2012 as the base year. The report on antibacterial drugs market also provides % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 to 2019. Key Topics Covered: Preface Executive Summary Market Overview Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/rh...ibacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Simulations Plus Releases ADMET Predictor Version 7.0
Business Wire - Wed Mar 26, 7:02AM CDT
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has released version 7.0 of its best-in-class ADMET Predictor(TM) molecular property prediction software.
Bayer Names Carnegie Science Center Recipient of $150,000 Bayer USA Foundation Grant
PR Newswire - Wed Mar 26, 7:00AM CDT
Bayer Corporation announced today that the Bayer USA Foundation has awarded the Carnegie Science Center (CSC) a three-year grant totaling $150,000 to support a range of STEM-related (science, technology, engineering and mathematics) programs, events and competitions at CSC's new Center for STEM Education and Career Development.
Global Dermatological Drugs Market 2014-2018: The Global Dermatological Drugs Market is Expected to Reap Large Revenues with Increasing Use of Biologics
M2 - Wed Mar 26, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/22gwrb/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Dermatological Drugs market to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market's growth is an increase in the aging population worldwide. The Global Dermatological Drugs market has also been witnessing a spurt in the use of biologics. However, the risk of adverse side effects associated with dermatological drugs could pose a challenge to the growth of this market. Key vendors dominating this space include AbbVie Inc., Galderma S.A., Johnson & Johnson Ltd., Novartis AG, Stiefel Laboratories Inc., and Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA. Commenting on the report, an analyst from the team said: Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. For more information visit http://www.researchandmarkets.com/research/22gwrb/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Global Hygiene Adhesives Market 2014-2018 with Bostik SA, H.B. Fuller Co., and Henkel AG & Co. KGaA. Dominating
M2 - Tue Mar 25, 11:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qh3qb5/global_hygiene) has announced the addition of the "Global Hygiene Adhesives Market 2014-2018" report to their offering. One of the main drivers in the Global Hygiene Adhesives market is the increasing focus vendors place on R&D. Vendors in this market are increasing their focus toward developing products that meet the standards set by the regulatory bodies monitoring the environment. In addition, changing customers' requirements, changing competitive scenarios, changing market dynamics, and better performance and productivity of technologically developed products, are the other key factors that are leading to vendors increasing their spending in R&D. Commenting on the report, an analyst from the team said: Emerging markets, such as China and India, are witnessing an increase in demand for hygiene products such as baby diapers and feminine napkins. This is due to the increasing preference shown by consumers in these regions as a result of the increase in their disposable income. However, it has been estimated that the penetration of baby diapers is approximately 20 percent in China and is less than 10 percent in India. This, therefore, creates a huge potential for vendors providing baby diapers to tap the unserved market and increase their market share. Vendors in the Global Hygiene Product market are also focusing on developing new hygiene products to meet the growing demand and to increase the use of hygiene products in these regions. Therefore, as the demand for hygiene products grows in these regions, the demand for hygiene adhesives is also expected to grow. Furthermore, vendors in the Global Hygiene Product market, who are the key end-users in the Global Hygiene Adhesives market, will also require new and innovative hygiene adhesive solutions from vendors in the Global Hygiene Adhesives market. This will result in them developing new and innovative hygiene products, thereby driving the growth in the market during the forecast period Further, the report states that despite the presence of several drivers, the growth of the Global Hygiene Adhesives market is curtailed by several challenges. One such challenge hindering the growth of the market is the increasing cost of raw materials. The increase in the requirement of raw materials by vendors to meet the rising demand for hygiene adhesives has increased the raw material supplier's power to price them as they deem fit. In addition, the increasing demand for raw materials in other application areas such as construction, packaging, and furniture making is also contributing to the volatility in raw material prices. Key vendors dominating this space are: - Bostik SA - H.B. Fuller Co. - Henkel AG & Co. KGaA. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Overview of Global Adhesives Market 07. Market Landscape 08. Market Segmentation by Application 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis Other Companies Featured: - 3M Corp. - Abifor AG - ADTEK Malaysia Sdn Bhd - ALFA Klebstoffe AG - Avery Dennison Corp. - BASF SE - Bayer AG - Beardow and Adams (Adhesives) Ltd. - C. L. Hauthaway Corp. - Clifton Adhesive Inc. - Cytec Industries Inc. - Eastman Chemical Company - Evonik Industries AG - Exxon Mobil Corp. - H.B. Fuller Co. - Huntsman Corp. - Ichemco srl. - Jowat AG - Lohmann GmbH & Co.KG - MACtac - OMNOVA Solutions Inc. - Sika AG - The Dow Chemical Co. - The Reynolds Co. - VIXXOL Corp. For more information visit http://www.researchandmarkets.com/research/qh...al_hygiene
Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating
M2 - Tue Mar 25, 10:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3c75md/global) has announced the addition of the "Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating" report to their offering. The Global Atherectomy and Thrombectomy Devices market to grow at a CAGR of 9.36 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing prevalence of abdominal aortic aneurysm and peripheral artery disease. The Global Atherectomy and Thrombectomy Devices market has also been witnessing the increase in demand for minimally invasive procedures. However, the lack of awareness about peripheral vascular disease among patients could pose a challenge to the growth of this market. There is an increasing demand for minimally invasive surgery among the rapidly increasing aging population in the world, and this is expected to propel the growth of the Global Atherectomy and Thrombectomy Devices market. Minimally invasive endovascular procedures are performed through minute incisions in the body. Such procedures can be used to treat plaque blockages in the arteries of the heart and other vessel walls of peripheral organs such as kidneys and brain. The principal advantages of these procedures, over conventional surgical methods, are the short recovery time, less physical trauma, minimal scarring, low risk of infection, minimal bleeding, low cost, and shorter hospital stays. Therefore, the increasing demand for minimally invasive surgery is expected to increase the demand for atherectomy and thrombectomy devices during the forecast period. Further, the report states that one of the major challenges faced by vendors in the market is the lack of awareness about PVDs among patients. This is primarily due to the asymptomatic nature of vascular diseases, wherein patients do not realize and are unaware of the immediate symptoms. The key vendors dominating this market space are: - Bayer AG - Boston Scientific Corp. - Covidien plc - Cardiovascular Systems Inc. - Spectranetics Corp. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Global Atherectomy and Thrombectomy Market 07. Market Segmentation by Product Category 08. Geographical Segmentation 09. Global Atherectomy Market 10. Market Segmentation by Product Type 11. Geographical Segmentation 12. Global Thrombectomy Devices Market 13. Market Segmentation by Procedure 14. Geographical Segmentation 15. Buying Criteria 16. Market Growth Drivers 17. Drivers and their Impact 18. Market Challenges 19. Impact of Drivers and Challenges 20. Market Trends 21. Trends and their Impact 22. Vendor Landscape For more information visit http://www.researchandmarkets.com/research/3c75md/global
1 Piece of News That Could Move Exelixis
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 24, 6:53PM CDT
Investors will soon learn whether Exelixis will be able to expand the use of its Cometriq cancer drug beyond its current indication as a therapy for medullary thyroid cancer, or MTC. Exelixis completed enrollment of patients in a phase 3 study...
3 Upcoming FDA Meetings You Should be Watching
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:05PM CDT
Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to...
Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
M2 - Fri Mar 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tp6b8p/diffuse_large) has announced the addition of the Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 report to their offering. Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Diffuse Large B-Cell Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diffuse Large B-Cell Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: Table of Contents Table of Contents List of Tables List of Figures Introduction Diffuse Large B-Cell Lymphoma Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Unaccomplished Trials of Diffuse Large B-Cell Lymphoma Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Prominent Drugs Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma Dec 09, 2013: Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial Aug 15, 2013: Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma Jun 16, 2013: Pharmacyclics Announces Results Of Two Phase II Ibrutinib Studies In Patients With Mantle Cell Lymphoma Or Diffuse Large B-Cell Lymphoma Jun 10, 2013: Immunomedics's 90Y-Epratuzumab Study Shows Improvement Of Therapy Results Following R-CHOP In Patients With Diffuse Large B-Cell Lymphoma May 10, 2013: Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint In Diffuse Large B-Cell Lymphoma Clinical Trial Profiles Clinical Trial Overview of Top Companies F. Hoffmann-La Roche Ltd. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Celgene Corporation Clinical Trial Overview of Celgene Corporation Amgen Inc. Clinical Trial Overview of Amgen Inc. Novartis AG Clinical Trial Overview of Novartis AG Takeda Pharmaceutical Company Limited Clinical Trial Overview of Takeda Pharmaceutical Company Limited Pharmacyclics, Inc. Clinical Trial Overview of Pharmacyclics, Inc. GlaxoSmithKline plc Clinical Trial Overview of GlaxoSmithKline plc Bayer AG Clinical Trial Overview of Bayer AG AstraZeneca PLC Clinical Trial Overview of AstraZeneca PLC Immunomedics, Inc. Clinical Trial Overview of Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government National Cancer Institute Clinical Trial Overview of National Cancer Institute Fred Hutchinson Cancer Research Center Clinical Trial Overview of Fred Hutchinson Cancer Research Center Groupe d'Etudes de Lymphomes de L'Adulte Clinical Trial Overview of Groupe d'Etudes de Lymphomes de L'Adulte Mayo Clinic Clinical Trial Overview of Mayo Clinic The University of Texas M. D. Anderson Cancer Center Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center FUDAN University Clinical Trial Overview of FUDAN University Memorial Sloan Kettering Cancer Center Clinical Trial Overview of Memorial Sloan Kettering Cancer Center The Lymphoma Academic Research Organisation Clinical Trial Overview of The Lymphoma Academic Research Organisation Massachusetts General Hospital Clinical Trial Overview of Massachusetts General Hospital Stanford University Clinical Trial Overview of Stanford University Five Key Clinical Profiles Appendix Abbreviations Definitions Research Methodology Secondary Research About Us Contact Us Disclaimer Source List of Tables Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Suspended Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Withdrawn Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Terminated Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Immunomedics, Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Groupe d'Etudes de Lymphomes de L'Adulte, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The Lymphoma Academic Research Organisation, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014- List of Figures Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2014- Therapeutics, Global, Clinical Trials In Progress by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- GlobalData Methodology For more information visit http://www.researchandmarkets.com/research/tp...fuse_large About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Can These Companies Bounce Back from Disappointing Sales?
Dan Carroll, The Motley Fool - Motley Fool - Fri Mar 21, 8:30AM CDT
Bristol-Myers Squibb and Pfizer have rallied back from the patent cliff as well as any companies in big pharma, and both these standout firms have looked toward the future in igniting investor optimism. But one drug captured all the hype around...
Why Pfizer Investors Should Watch Quark This Summer
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 19, 1:30PM CDT
Pfizer may learn whether it has a potential challenger to Novartis' and Roche's Lucentis and Regeneron and Bayer's Eylea soon. Its development partner, Quark Pharmaceuticals , is expected to complete its phase 2b study of PF-655 in...
Update on Bayer's Adempas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 17, 1:23PM CDT
Bayer initiated the phase IIIb study on Adempas.
5 Big Pharma Stocks With the Strongest Ties to Emerging Markets
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 16, 1:05PM CDT
The life of a buy-and-hold pharmaceuticals investor used to be fairly simple in the 1990s and 2000s. They would sit back, relax, and enjoy their 80%-plus gross margin and premium dividend yield without a care in the world. But times have changed. ...
Siemens' Microbiology Unit Up for Sale? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 4:00PM CDT
According to a Bloomberg report, Siemens is contemplating the sale of its microbiology unit to stop the slide in profitability.
Bright Outlook at Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 3:45PM CDT
Bayer divulged its sales growth expectations for three of its major segments through 2016.
Bayer/Amgen's Nexavar Fails in Late-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:45PM CDT
Bayer and Amgen announced disappointing results from a phase III study on Nexavar.
